Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 24Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

3-Iodobenzylguanidine 2Cyclophosphamide 2Gemcitabine 2Insulin Infusion Systems 2Powders 2Suspensions 2balstilimab 2leronlimab 2ruxolitinib 2talquetamab 2Abiraterone Acetate 1Alpelisib 1Androgen Antagonists 1Asparaginase 1Bone Marrow Transplantation 1Capecitabine 1Docetaxel 1Eflornithine 1HMPL-013 1Hydrocortisone 1Immunotherapy, Adoptive 1LY3023414 1Magnetic Resonance Spectroscopy 1Methionine 1Nivolumab 1Paclitaxel 1Peripheral Blood Stem Cell Transplantation 1Prednisolone 1Prednisone 1Proton Pump Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × adagrasib × 1 year × Clear all
NCT05162443 2025-08-26

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Bristol-Myers Squibb

Approved for marketing
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡